CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 86 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2017. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $74,030,000 | -21.0% | 626,789 | -25.7% | 0.08% | -14.9% |
Q3 2020 | $93,694,000 | +47.1% | 843,027 | +35.3% | 0.09% | +70.9% |
Q2 2020 | $63,673,000 | +134.7% | 623,141 | +147.9% | 0.06% | +111.5% |
Q1 2020 | $27,133,000 | +410.1% | 251,396 | +450.1% | 0.03% | +550.0% |
Q4 2019 | $5,319,000 | +209.8% | 45,700 | +204.7% | 0.00% | +300.0% |
Q3 2019 | $1,717,000 | +98.0% | 15,000 | +64.8% | 0.00% | 0.0% |
Q2 2019 | $867,000 | -69.4% | 9,100 | -70.6% | 0.00% | -66.7% |
Q1 2019 | $2,829,000 | +360.0% | 31,000 | +282.7% | 0.00% | +200.0% |
Q4 2018 | $615,000 | -86.0% | 8,100 | -85.2% | 0.00% | -80.0% |
Q3 2018 | $4,384,000 | -79.4% | 54,800 | -76.7% | 0.01% | -58.3% |
Q2 2018 | $21,325,000 | +135.7% | 235,300 | +110.7% | 0.01% | +20.0% |
Q1 2018 | $9,048,000 | +12.3% | 111,700 | +9.2% | 0.01% | +11.1% |
Q4 2017 | $8,058,000 | -56.8% | 102,300 | -49.4% | 0.01% | -59.1% |
Q3 2017 | $18,648,000 | – | 202,100 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kite Lake Capital Management (UK) LLP | 301,773 | $30,835,000 | 47.96% |
Maso Capital Partners Ltd | 948,629 | $96,931,000 | 39.10% |
Athos Capital Ltd | 269,832 | $27,571,000 | 18.83% |
York Capital Management Global Advisors, LLC | 1,347,897 | $137,728,000 | 9.09% |
Sand Grove Capital Management LLP | 351,661 | $35,933,000 | 6.83% |
HHLR ADVISORS, LTD. | 2,962,076 | $302,665,000 | 2.77% |
Ovata Capital Management Ltd | 37,000 | $3,781,000 | 1.13% |
Temasek Holdings (Private) Ltd | 1,240,000 | $126,703,000 | 0.76% |
Pentwater Capital Management LP | 399,570 | $40,828,000 | 0.73% |
Campbell & CO Investment Adviser LLC | 2,200 | $225,000 | 0.28% |